Literature DB >> 447835

Hemoglobin Indianapolis (beta 112[G14] arginine). An unstable beta-chain variant producing the phenotype of severe beta-thalassemia.

J G Adams, L A Boxer, R L Baehner, B G Forget, G A Tsistrakis, M H Steinberg.   

Abstract

Hemoglobin (Hb) Indianapolis is an extremely labile beta-chain variant, present in such small amounts that it was undetectable by usual techniques. Clinically, it produces the phenotype of severe beta-thalassemia. Biosynthetic studies showed a beta:alpha ratio of 0.5 in reticulocytes and about 1.0 in marrow after a 1-h incubation. These results, similar to those seen in typical heterozygous beta-thalassemia, suggested that betaIndianapolis was destroyed so rapidly that its net synthesis was essentially zero. To examine the kinetics of globin synthesis, reticulocyte incubations of 1.25--20 min were performed with [3H]leucine. The betaIndianapolis:beta A ratio at 1.25 min was 0.80 suggesting that beta Indianapolis was synthesized at a near normal rate. At 20 min, this ratio was 0.46 reflecting rapid turnover of beta Indianapolis. The erythrocyte ghosts from these incubations contained only betaIndianapolis and alpha-chains, and the proportion of betaIndianapolis decreased with time, indicating loss of betaIndianapolis. Pulse-chase studies showed little change in beta A:alpha ratio and decreasing betaIndianapolis:alpha and betaIndianapolis:beta A with time. The half-life of betaIndianapolis in the soluble hemoglobin was approximately equal to 7 min. There was also rapid loss of beta Indianapolis from the erythrocyte membrane. From these results, it may be inferred that betaIndianapolis is rapidly precipitated from the soluble cell phase to the membrane, where it is catabolized. Heterozygotes for beta 0-thalassemia usually have minimal hematologic abnormalities, whereas heterozygotes with betaIndianapolis, having a similar net content of beta-chain, have severe disease. The extremely rapid precipitation and catabolism of betaIndianapolis and the resulting excess of alpha-chains, both causing membrane damage, may be responsible for the severe clinical manifestations associated with this variant. It seems likely that other, similar disturbances in the primary sequence of globin polypeptide chains may produce clinical findings similar to those seen with hemoglobin Indianapolis and thus produce the phenotype of severe beta-thalassemia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 447835      PMCID: PMC372034          DOI: 10.1172/JCI109393

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.

Authors:  P I TERASAKI; J D MCCLELLAND
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

2.  The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes.

Authors:  J T DODGE; C MITCHELL; D J HANAHAN
Journal:  Arch Biochem Biophys       Date:  1963-01       Impact factor: 4.013

3.  Studies of congenital hemolytic syndromes. I. Rates of destruction and production of erythrocytes in thalassemia.

Authors:  M E ERLANDSON; I SCHULMAN; G STERN; C H SMITH
Journal:  Pediatrics       Date:  1958-11       Impact factor: 7.124

4.  Abnormal or absent beta mRNA in betao Ferrara and gene deletion in delta beta thalassaemia.

Authors:  F Ramirez; J V O'Donnell; P A Marks; A Bank; S Musumeci; G Schilirò; G Pizzarelli; G Russo; B Luppis; R Gambino
Journal:  Nature       Date:  1976-10-07       Impact factor: 49.962

5.  Evidence for rapid loss of newly synthesized haemoglobin S molecules in sickle cell anaemia and sickle cell trait.

Authors:  J DeSimone; J G Adams; J Shaeffer
Journal:  Br J Haematol       Date:  1977-03       Impact factor: 6.998

6.  Identification of a nondeletion defect in alpha-thalassemia.

Authors:  Y W Kan; A M Dozy; R Trecartin; D Todd
Journal:  N Engl J Med       Date:  1977-11-17       Impact factor: 91.245

7.  The thalassemia syndromes.

Authors:  A Bank
Journal:  Blood       Date:  1978-03       Impact factor: 22.113

8.  Erythropoiesis and the effect of transfusion in homozygous beta-thalassemia.

Authors:  I Cavill; C Ricketts; A Jacobs; E Letsky
Journal:  N Engl J Med       Date:  1978-04-06       Impact factor: 91.245

9.  beta-Thalassemia arising as a new mutation in an American child.

Authors:  P A Nronha; G R Honig
Journal:  Am J Hematol       Date:  1978       Impact factor: 10.047

10.  Decreased globin messenger RNA in thalassemia detected by molecular hybridization.

Authors:  D L Kacian; R Gambino; L W Dow; E Grossbard; C Natta; F Ramirez; S Spiegelman; P A Marks; A Bank
Journal:  Proc Natl Acad Sci U S A       Date:  1973-06       Impact factor: 11.205

View more
  20 in total

1.  Beta-thalassaemia: molecular pathogenesis and clinical variability.

Authors:  A E Kulozik
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

Review 2.  Thalassemia: genotypes and phenotypes.

Authors:  D Loukopoulos
Journal:  Ann Hematol       Date:  1991-05       Impact factor: 3.673

Review 3.  Thalassemia: genotypes and phenotypes.

Authors:  D Loukopoulos
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

4.  Molecular basis for dominantly inherited inclusion body beta-thalassemia.

Authors:  S L Thein; C Hesketh; P Taylor; I J Temperley; R M Hutchinson; J M Old; W G Wood; J B Clegg; D J Weatherall
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

5.  The William Allan Memorial Award address: Thalassemia: molecular mechanism and detection.

Authors:  Y W Kan
Journal:  Am J Hum Genet       Date:  1986-01       Impact factor: 11.025

Review 6.  Hemoglobin variants: biochemical properties and clinical correlates.

Authors:  Christopher S Thom; Claire F Dickson; David A Gell; Mitchell J Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

7.  Molecular abnormalities of a human glucose-6-phosphate dehydrogenase variant associated with undetectable enzyme activity and immunologically cross-reacting material.

Authors:  M Maeda; P Constantoulakis; C S Chen; G Stamatoyannopoulos; A Yoshida
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

8.  alpha-Thalassemia caused by an unstable alpha-globin mutant.

Authors:  S A Liebhaber; Y W Kan
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

9.  Molecular analysis of the beta-thalassemia phenotype associated with inheritance of hemoglobin E (alpha 2 beta2(26)Glu leads to Lys).

Authors:  E J Benz; B W Berman; B L Tonkonow; E Coupal; T Coates; L A Boxer; A Altman; J G Adams
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

10.  Molecular basis for nondeletion alpha-thalassemia in American blacks. Alpha 2(116GAG----UAG).

Authors:  S A Liebhaber; M B Coleman; J G Adams; F E Cash; M H Steinberg
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.